TEPSIN

Across TCGA pan-cancer cohorts, TEPSIN mass-spec protein is linked to patient survival in 3 of 34 cancer types, making it a survival-associated TEPSIN data layer compared with 23 for mass-spec protein and 9 for mutation status.

The strongest signal is observed in lung adenocarcinoma (LUAD), where higher TEPSIN mass-spec protein is associated with worse disease-free survival. In most high-consensus cancer types, elevated TEPSIN expression acts as an unfavorable survival marker.

LUAD, PDAC, and HNSC are the cancer types where TEPSIN mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
LUAD	DFS	Tertile	II,III,IV	0.279	0.794	.005	17	view →
PDAC	OS	Tertile	III,IV	0.124	0.685	.026	6	view →
HNSC	DFS	Median	III,IV	0.926	1.000	.020	3	view →

Pink = unfavorable, green = favorable. Showing the 3 strongest of 3 lineages.

TEPSIN–LUAD (DFS)

Open the LUAD breakdown →